A
Anne Schuind
Researcher at GlaxoSmithKline
Publications - 72
Citations - 5652
Anne Schuind is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Vaccination & Zoster vaccine. The author has an hindex of 22, co-authored 68 publications receiving 5248 citations. Previous affiliations of Anne Schuind include Universidade Federal do Rio Grande do Sul.
Papers
More filters
Journal ArticleDOI
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial
Diane M. Harper,Eduardo L. Franco,Cosette M. Wheeler,Daron G. Ferris,D. G. Jenkins,Anne Schuind,Toufik Zahaf,Bruce L. Innis,Paulo Naud,Newton Sérgio de Carvalho,Cecilia Roteli-Martins,Julio Cesar Teixeira,Mark M. Blatter,A. Korn,Wim Quint,Gary Dubin +15 more
TL;DR: The bivalent HPV vaccine was efficacious in prevention of incident and persistent cervical infections with HPV-16 and HPV-18, and associated cytological abnormalities and lesions.
Journal ArticleDOI
Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
Diane M. Harper,Eduardo L. Franco,Cosette M. Wheeler,Anna-Barbara Moscicki,Barbara Romanowski,Cecilia Roteli-Martins,D. G. Jenkins,Anne Schuind,Sue Ann Costa Clemens,Gary Dubin +9 more
TL;DR: Broad protection against cytohistological outcomes beyond that anticipated for HPV 16/18 and protection against incident infection with HPV 45 and HPV 31 is noted and the vaccine has a good long-term safety profile.
Journal ArticleDOI
Comparison of the immunogenicity and safety of Cervarix™ and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years
Mark H. Einstein,Mira Baron,Myron J. Levin,Archana Chatterjee,Robert P. Edwards,Fred Zepp,Isabelle Carletti,Francis Dessy,Andrew F. Trofa,Anne Schuind,Gary Dubin +10 more
TL;DR: In the total vaccinated cohort (all women who received at least one vaccine dose, regardless of their serological and DNA status prior to vaccination), Cervarix™ induced significantly higher serum neutralizing antibody titers in all age strata.
Journal ArticleDOI
Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years.
Barbara Romanowski,de Borba Pc,Paulo Naud,Cecilia Roteli-Martins,De Carvalho Ns,Julio Cesar Teixeira,Fred Y. Aoki,Brian Ramjattan,Shier Rm,Somani R,Barbier S,Mark M. Blatter,Chambers C,Daron G. Ferris,Stanley A. Gall,Guerra Fa,Diane M. Harper,James Hedrick,Henry Dc,A. Korn,Kroll R,Anna-Barbara Moscicki,Rosenfeld Wd,Sullivan Bj,Thoming Cs,Stephen K. Tyring,Cosette M. Wheeler,Gary Dubin,Anne Schuind,Toufik Zahaf,Greenacre M,Sgriobhadair A +31 more
TL;DR: The findings show excellent long-term efficacy, high and sustained immunogenicity, and favourable safety of the HPV-16/18 AS04-adjuvanted vaccine up to 6.4 years.
Journal ArticleDOI
Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: Results from a randomized study
Barbara Romanowski,Tino F. Schwarz,Linda Ferguson,Klaus Peters,Marc Dionne,Karin Schulze,Brian Ramjattan,Peter Hillemanns,Grégory Catteau,Kurt Dobbelaere,Anne Schuind,Dominique Descamps +11 more
TL;DR: The results indicate that the HPV-16/18 vaccine on a 2D M0,6 schedule is immunogenic and generally well tolerated in girls 9-14 years and that the 2D schedule is likely adequate for younger females.